Down-regulation of p110β expression increases chemosensitivity of colon cancer cell lines to oxaliplatin

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 32, Issue 2, 2012, Pages 280-286

  Liu, Weicheng ^a   Wang, Guihua ^a   Cao, Xiaonian ^a   Luo, Xuelai ^a   Li, Zhaoming ^a   Deng, Yu ^a   Li, Xiaolan ^a   Wang, Shijia ^b   Liu, Mengfei ^b   Hu, Junbo ^a   Wang, Jing ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cell apoptosis; Cell proliferation; Colon cancer cells; Oxaliplatin; p110

Indexed keywords

ANTINEOPLASTIC AGENT; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CB PROTEIN, HUMAN; PLATINUM COMPLEX;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; COLON TUMOR; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; ORGANOPLATINUM COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84861132180     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-012-0049-z     Document Type: Article

References (32)

1. Koyasu, S. The role of PI3K in immune cells. Nat Immunol, 2003, 4(4):313-319
2. Myou S, Leff AR, Myo S, et al. Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. J Exp Med, 2003, 198(10): 1573-1582 (Pubitemid 37467171)
3. Fruman DA, Snapper SB, Yballe CM, et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85 alpha. Science, 1999, 283(5400): 393-397
4. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nature Rev Immunol, 2003, 3(4):317-330 (Pubitemid 37328684)
5. Jia SD, Liu ZN, Zhang S, et al. Essential roles of PI(3)K-p110b in cell growth, metabolism and tumorigenesis. Nature, 2008, 454(7205):776-779
6. Muller CI, Miller CW, Hofmann WK, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res, 2007, 31(1):27-32 (Pubitemid 44709746)
7. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer- specific mutations in PIK3CA show gain of function. PNAS, 2007, 104(13):5569-5574 (Pubitemid 47175721)
8. Ma YY, Wei SJ, Lin YC, et al. PIK3CA as an oncogene in cervical cancer. Oncogene, 2000, 19(23):2739-2744
9. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science, 2004, 304(5670):554 (Pubitemid 38541907)
10. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer, Nat Genet, 1999, 21(1): 99-102 (Pubitemid 29036292)
11. Hill KM, Kalifa S, Das JR, et al. The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells. Prostate, 2010, 70(7): 755-764
12. Ciraolo E, Iezzi M, Marone R, et al. Phosphoinositide 3-kinase p110β activity: key role in metabolism and mammary gland cancer but not development. Sci Signal, 2008, 1(36):1-12
13. Carvalho S, Milanezi F, Costa JL, et al. PIKing the right isoform: the emergent role of the p110β subunit in breast cancer. Virchows Arch, 2010, 456(3):235-243
14. Toscano F, Parmentier B, Fajoui ZE, et al. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells. Biochem Pharmacol, 2007, 74(3):392-406 (Pubitemid 46963236)
15. Cheng JQ, Lindsley CW, Cheng GZ, et al. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene, 2005, 24(50):7482-7492 (Pubitemid 41637988)
16. Xia S, Yu S, Fu Q, et al. Inhibiting PI3K/Akt pathway increases DNA damage of cervical carcinoma HeLa cells by drug radiosensitization. J Huazhong Univ Sci Technol [Med Sci], 2010, 30(3):360-364
17. Wu Q, Chen Y, Cui G, et al. Wortmannin inhibits K562 leukemic cells by regulating PI3k/Akt channel in vitro. J Huazhong Univ Sci Technol [Med Sci], 2009, 29(4): 451-456
18. Rudelius M, Pittaluga S, Nishizuka S, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood, 2006, 108(5): 1668-1676 (Pubitemid 44316136)
19. Leverrier Y, Okkenhaug K, Sawyer C, et al. Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages. J Biol Chem, 2003, 278(40):38437-38442 (Pubitemid 37221737)
20. Denley A, Kang S, Karst U, et al. Oncogenic signaling of class I PI3K isoforms. Oncogene, 2008, 27(18):2561-2574 (Pubitemid 351550883)
21. MathenyRW Jr, Adamo ML. PI3K p110α and p110β have differential effects on Akt activation and protection against oxidative stress-induced apoptosis in myoblasts. Cell Death Differ, 2010, 17(4):677-688
22. Marqués M, Kumar A, Cortés I, et al. Phosphoinositide 3-kinases p110α and p110β regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell Biol, 2008, 28(8):2803-688
23. Czauderna F, Fechtner M, Aygun H, et al. Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed shRNA. Nucleic Acids Res, 2003, 31(2):670-682 (Pubitemid 36175957)
24. Pu P, Kang C, Zhang Z, et al. Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo. Technol Cancer Res Treat, 2006, 5(3): 271-280 (Pubitemid 43946260)
25. Kumara A, Fernandez-Capetillob O, Carreraa AC. Nuclear phosphoinositide 3-kinase β controls doublestrand break DNA repair. PNAS, 2010, 107(16):7491-7496
26. Brown EJ. Analysis of cell cycle progression and genomic integrity in early lethal knockouts. Methods Mol Biol, 2004, 280:201-212
27. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev, 2001, 15(17):2177-2196 (Pubitemid 32843830)
28. Wang X, Li M, Wang J, et al. The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells. Biochem Pharmacol, 2006, 71(11): 1540-1550
29. Liu HF, Hu HC, Chao JI. Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells. Chemico Biological Interactions, 2010, 188(3):535-545
30. Hochster H, Chachoua A, Speyer J, et al. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol, 2003, 21(14):2703-2707 (Pubitemid 46606314)
31. Chaney SG, Campbell SL, Bassett E, et al. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol, 2005, 53(1):3-11 (Pubitemid 39656106)
32. Raymond E, Faivre S, Chaney S, et al. Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther, 2002, 1(3):227-235